CLDN18 and gastric cancer: The survival outcome meta-analysis of the <i>CLDN18-ARHGAP</i> fusion gene showed that it was associated with overall survival outcomes in gastric cancer (HR, 2.03, 95% CI 1.26-3.26, <i>P</i> < 0.01, random-effects).